Reported Late Wednesday March 08, Neoleukin Therapeutics Provides Strategic Update And Announces Restructuring And Leadership Transition; Chief Executive Officer Jonathan Drachman, M.D., Will Be Stepping Down After A Short Transition
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has
HC Wainwright & Co. Downgrades Neoleukin Therapeutics to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Gainers
Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.
Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength
Neoleukin Therapeutics Inc (NASDAQ:NLTX) announced discontinuing the development of NL-201 for strategic reasons. Preliminary monotherapy data from the Phase 1 study…
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.
Guggenheim Downgrades Neoleukin Therapeutics to Neutral
Guggenheim analyst Michael Schmidt downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.
